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ABSTRACT
DNA methylation is thought to induce transcrip-
tional silencing through the combination of two
mechanisms: the repulsion of transcriptional activa-
tors unable to bind their target sites when methy-
lated, and the recruitment of transcriptional repres-
sors with specific affinity for methylated DNA. The
Methyl CpG Binding Domain proteins MeCP2, MBD1
and MBD2 belong to the latter category. Here, we
present MBD2 ChIPseq data obtained from the en-
dogenous MBD2 in an isogenic cellular model of
oncogenic transformation of human mammary cells.
In immortalized (HMEC-hTERT) or transformed (HM-
LER) cells, MBD2 was found in a large proportion
of methylated regions and associated with transcrip-
tional silencing. A redistribution of MBD2 on methy-
lated DNA occurred during oncogenic transforma-
tion, frequently independently of local DNA methy-
lation changes. Genes downregulated during HMEC-
hTERT transformation preferentially gained MBD2 on
their promoter. Furthermore, depletion of MBD2 in-
duced an upregulation of MBD2-bound genes methy-
lated at their promoter regions, in HMLER cells.
Among the 3,160 genes downregulated in trans-
formed cells, 380 genes were methylated at their
promoter regions in both cell lines, specifically as-
sociated by MBD2 in HMLER cells, and upregu-
lated upon MBD2 depletion in HMLER. The tran-
scriptional MBD2-dependent downregulation occur-
ring during oncogenic transformation was also ob-
served in two additional models of mammary cell
transformation. Thus, the dynamics of MBD2 deposi-
tion across methylated DNA regions was associated
with the oncogenic transformation of human mam-
mary cells.
INTRODUCTION
In vertebrates, DNA methylation at transcriptional start
sites (TSSs) is an epigenetic modification associated with
the downregulation of gene transcription (1). This epige-
netic modification has been extensively studied during cell
differentiation and neoplastic transformation, since DNA
methylation changes are associated with these biological
processes andmay be involved in the control of gene expres-
sion (2–4). Although DNAmethylation at specific sites can
impair the direct binding of transcription factors to their
targets and, in turn, may lead to transcriptional downreg-
ulation (5–8), these epigenetic signals are also interpreted
by specific proteins (9). These proteins have been classified
into three families (10–12) according to their methyl-DNA
binding domain: the methyl-CpG binding domain (MBD)
proteins; the UHRF proteins that bind methylated DNA
through there SRA domain proteins; and a subclass of zinc
finger proteins that preferentially bind methylated DNA se-
quences (ZBTB33, ZBTB4, ZBTB38, ZFP57, KLF4).
MeCP2, MBD1, MBD2 and MBD4 are members of
the MBD protein family that recognize methylated CpG
sites independently of their surrounding sequences in vitro
(13). In human cells and Xenopus oocytes these proteins
are found associated with chromatin remodeling complexes
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along with histone deacetylases and/or histone methylases
(14–18). The ability of these proteins to recruit repressor
complexes at methylated CpG sites has suggested a direct
relationship between DNA methylation and the establish-
ment of a repressive chromatin architecture. However, more
recent findings suggesting that MBD proteins may also be
involved in other mechanisms such as alternative splicing
and gene activation (19–21) have tempered this concept.
Several genome maps of MBD2 deposition have been
constructed from human and mouse cells. Analysis of
MBD2 binding sites at 25 000 promoter regions indi-
cates that the promoter regions targeted by the endogenous
MBD2 proteins aremethylated and depleted for RNApoly-
merase II (22). Furthermore, parallel sequencing of chro-
matin immunoprecipitated fragments (ChIPseq) obtained
from human HeLa and MCF7 cells expressing tagged-
MBD2 vectors has shown that that MBD2 binding sites are
methylated and that MBD2 deposition at TSS regions is
associated with genes exhibiting repressive histone marks
(21,23). A linear relationship between DNA methylation
and MBD2 deposition is observed in mouse ES cells and
derived neuronal cells expressing biotin-taggedMBD2 pro-
teins from a single copy transgene (24). Although these
studies show that a small fraction of MBD2 binding sites
at promoter regions may be unmethylated and correspond
to actively transcribed genes, these genome-wide analyses
indicate that the presence of MBD2 at TSS regions is pre-
dominantly associated with methylated genes exhibiting a
low transcriptional activity. Altogether, this suggests that
MBD2 acts mainly as a methylation-dependent transcrip-
tional repressor.
As expected from a transcriptional repressor involved in
epigenetic mechanisms, MBD2 seems to play a role in the
acquisition of specific phenotypes. MBD2 can block full re-
programming of somatic to iPS cells through direct bind-
ing toNANOG promoter elements thereby preventing tran-
scriptional activation (25). In mice, MBD2 deletion alters
the immune response (26), protects mice from hind-limb is-
chemia (27) and greatly reduces the number of intestinal
adenoma in tumor-prone APCmin mice (28,29), mimicking
the effects of experimentally induced DNA hypomethyla-
tion (30,31). Detailed gene candidate analysis indicates that
MBD2 controls the expression of some exocrine pancreatic
genes in a tissue-specific manner in mice (32). For exam-
ple, TFF2 is expressed in duodenum and silenced in colon,
while this gene is methylated in both tissues. This tissue-
specific repression is correlated with the tissue-specific pres-
ence ofMBD2 atTFF2 promoter andMBD2 deletion leads
to TFF2 upregulation in colon (32), suggesting that the dy-
namics of MBD2 binding has a direct effect on gene tran-
scription. Taken together these data suggest that the cell-
specific transcriptional repression occurring during differ-
entiation or transformation may be associated, at least for
some genes, with a redistribution ofMBD2 proteins among
methylated DNA regions.
In order to address this question we analyzed MBD2
binding sites in an isogenic cellular model of oncogenic
transformation of human mammary epithelial cells con-
structed from the progression model described by Wein-
berg and colleagues (33). Human mammary cells were im-
mortalized through the introduction of the human telom-
erase catalytic subunit gene (hTERT). The resulting immor-
talized cell line (HMEC-hTERT) was transformed by the
introduction of the SV40 T/t antigens and oncogenic H-
RASV12 genes (HMLER cell line). In a similar model con-
structed from human fetal lung fibroblasts (MRC-5 cells), it
has been shown that DNA methylation changes occur pre-
dominantly during hTERT-induced immortalization while
only subtle changes are associated with the transformation
by SV40 large T-antigen and H-RASV12 (34). Thus, the
comparison of HMEC-hTERT and HMLER cells offers
the opportunity to investigate the potential modifications
of MBD2 binding site associated with the acquisition of a
specific phenotype in an isogenic background with a minor
contribution of DNA methylation changes.
MATERIALS AND METHODS
Cell lines
HMEC-hTERT, HMLER, HME-ZEB1-RAS and mes-
enchymal HME-shP53-RAS cell lines were kindly provided
by Anne-Pierre Morel (CRCL, Lyon, France) and cultured
as previously described (35,36).
Treatments
Cells were seeded at 1.105 per well in six-well plates.
The day after plating, cells were either transfected with
100 pmol of MBD2 targeting siRNA (siMBD2; sens:
5′-GGAGGAAGUGAUCCGAAAdTdT-3′) or control
siRNA (siCtrl; Sigma-Aldrich, Saint Louis, MO, USA,
MISSION siRNA Universal Negative Controls #1) using
Lipofectamine-2000 (Sigma-Aldrich) as specified by the
manufacturer’s instructions, or treated every day with 10
M of DAC (Sigma-Aldrich). Cells were collected 72 h
after the start of the treatments.
Western-blot
Around 1.0 × 106 cells were lysed in NuPage LDS Sample
Buffer and Reducing Agent (Life Technologies, Carlsbad,
CA, USA). Lysates were sonicated and heated at 95◦C for
10 min. After migration and transfer, membranes were in-
cubated with either anti-MBD2 (Santa Cruz, Heidelberg,
Germany, sc-9397) or anti-ß-Actin (Sigma-Aldrich, A5441)
antibodies.
RNA extraction
Total RNA was extracted using the NucleoSpin RNA
kit (Macherey-Nagel, Hoerdt, France) following manufac-
turer’s instructions. RNA purity, integrity and quantifica-
tion were assessed using agarose gel-electrophoresis and
analysis on aNanoDrop 1000 (Thermo Scientific,Wilming-
ton, DE, USA). Pools of three to five independent extrac-
tions were sent for high-throughput sequencing to MGX-
Montpellier GenomiX (library preparation with the TruSeq
RNA sample preparation Kit from Illumina, followed by
single-end 50 bp sequencing on Illumina HiSeq 2000).
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Digestion of genomic DNA
Genomic DNA was extracted from cell lines using the QI-
Aamp DNAMini Kit (Qiagen, Courtaboeuf, France). Two
hundred micrograms of DNA were digested overnight at
37◦C with either HpaII or MspI restriction enzymes (New
England BioLabs, Evry, France), and analyzed on ethidium
bromide-containing agarose gels.
Methylated-DNA precipitation sequencing (MeDPseq)
Genomic DNA was sheared by sonication (final fragments
ranged between 300 and 500 bp). Methylated-DNA pre-
cipitations (MeDP) were performed from 1 g of sheared
DNA using the MethylMiner Methylated DNA Enrich-
ment Kit (Life Technologies). Library preparation and
high-throughput sequencing (single-end 50 bp sequencing
on Illumina HiSeq 2000) were performed at Beijing Ge-
nomics Institute (Hong-Kong, China) from pools of five in-
dependent experiments.
Chromatin immunoprecipitation
MBD2 Chromatin immunoprecipitations (ChIP) were per-
formed as previously described (37). Briefly, sheared chro-
matin (with a mean fragment length between 300 and 500
bp) was obtained by sonication of formaldehyde cross-
linked nuclei. ChIP were then performed with a custom-
made rabbit polyclonal antiserumobtained after immuniza-
tion with peptides corresponding to the N-terminal part of
the MBD2 protein (Covalab, Villeurbanne, Lyon) (38) us-
ing the ChIP Assay Kit (Merck Millipore, Saint-Quentin-
en-Yvelines, France) as specified by the manufacturer’s in-
struction. Precipitated DNA was finally purified using Nu-
cleoSpin Gel and PCR Clean-up kit, (Macherey-Nagel) ac-
cording to the manufacturer’s protocol ‘DNA clean-up of
samples containing SDS.’
Input and bound fractions of DNA were dosed by flu-
orometry (Qubit 2.0, Life Technologies). Pools of five in-
dependent experiments were sent for high-throughput se-
quencing to ProfileXpert (Lyon, France) (library prepara-
tion and single-end 50 bp sequencing on Illumina HiSeq
2000).
Alternatively, enrichment in the bound fraction as com-
pared to the input was measured by qPCR for several re-
gions, using iQ SYBR Green supermix (BiroRad). Primer
sequences and corresponding hybridization temperatures
are listed in Supplementary Table S1.
ChIP-chip and MeDP-chip
ChIP-chip and MeDP-chip experiments were performed
as previously described (22). Briefly, chromatin fragments
were precipitated with anti-MBD2 antibody (Covalab), and
DNA fragments were precipitated using a His6-tagged re-
combinant protein containing four MBD domains cloned
from MBD1 (39). The DNA fragments from the ChIP and
MeDP experiments were amplified by random PCR. The
samples were then labeled with the GeneChip WT Double-
Stranded DNA Terminal Labeling Kit and hybridized to
the human tiling arrays (Human Promoter 1.0R Arrays),
which were then washed and scanned by ProfileXpert ser-
vice (Lyon, France) according to Affymetrix protocols.
Microarray signals were analyzed using aroma.affymetrix
package on the hg18 reference genome.
DNA methylation analysis
Bisulfite sequencing, used to determine the CpG methy-
lation patterns of tens regions (Supplementary Table S2),
was performed as described in (40). Briefly, after a first
amplification using sequence-specific primers, PCR frag-
ments were tagged in a second amplification step and se-
quenced using the Roche/454 GS junior system accord-
ing to the manufacturer’s protocol (Roche emPCR Am-
plification Method Manual – Lib-A and Roche Sequenc-
ing Method Manual). The mean number of reads per
sample was 475, see Supplementary Table S2. Data were
analyzed using Amplikyzer (https://pypi.python.org/pypi/
amplikyzer/0.97).
RNAseq analysis
Reads were aligned on the UCSC Homo sapiens hg19
genome using TopHat2 (41). Differential expression analy-
sis was performed as described in (42), using the Bioconduc-
tor package edgeR (43). Only genes with at least 1 read per
million (RPM) in at least two of the samples were kept for
subsequent analyses. Enriched Gene Ontology terms and
KEGGpathway were identified usingGene Set Enrichment
Analysis (44) with genes pre-ranked according to their fold
change induced by siMBD2 treatment.
ChIPseq analysis
Reads were aligned on the UCSC Homo sapiens hg19
genome using Bowtie (45). Duplicate reads were filtered
using SAMTools (46) to limit PCR induced biases. Pre-
liminary peak detection was performed using Model-based
Analysis of ChIP-Seq (MACS) (47). Over sequenced re-
gions were defined as 500 bp regions containing more than
three times the median number of reads in at least one of
the two inputs. Peaks were filtered against these over se-
quenced regions, as they represent suspicious false positive
regions. Peaks in HMEC-hTERT and HMLER were com-
pared using MAnorm (48), and peaks common to both cell
lines or cell line specific peaks (P value ≤ 0.01) were de-
termined. Read density visualization at specific locations
were drawn with Sushi.R (49). K-mean clusterization of
peaks and subsequent visualization were performed with
seqMINER (50). Integrative analysis of ChIPseq, RNAseq
and ChIP-chip data was performed using the Bioconductor
package Repitools (51). Top enriched motifs in peaks were
obtained using the RSAT oligo-diff tool (52).
Data deposition
The ChIPseq, the RNAseq and the microarray data from
this publication have been submitted to the GEO database
as entry GSE63237.
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RESULTS
Identification of MDB2 binding sites and methylated DNA
regions in HMEC-hTERT and HMLER cells
To identify possiblemodifications ofMBD2deposition pro-
files associated with phenotype changes, genome-wide anal-
yses (ChIPseq) were performed in an isogenic cellularmodel
(Figure 1A) constructed from immortalized HMEC cells
(HMEC-hTERT cells) transformed by expressing SV40T/t
antigen and H-RASV12 (33,35). In this study, we focused
on the endogenous protein in order to take into account
the potential changes in the regulation of MBD2 during
the transformation process. In parallel, we identifiedmethy-
lated DNA regions by MeDPseq experiments performed in
both cell lines using the MethylMiner kit (Invitrogen) for
selecting methylated DNA regions.
Methylated DNA regions and MBD2 peaks were iden-
tified from the aligned reads (sequenced fragments) (Fig-
ure 1B). These data were compared with ChIP-chip and
MeDP-chip data obtained using an array representing
25,500 promoter regions (Human Promoter 1.0R array,
Affymetrix). Methylated regions identified by MeDPseq
were enriched in MeDP-chip experiments performed with
recombinant proteins containing four MBD domains from
MBD1 (22,39) (Supplementary Figure S1A and B). Simi-
larly, MBD2 peaks identified from ChIPseq were enriched
in MBD2 ChIP-chip (Supplementary Figure S1C and D).
Next, a group of genomic regions sharing the same char-
acteristics (MBD2 binding and DNA methylation) in both
cell lines was analyzed by ChIP-qPCR (Figure 2A). Data
obtained indicated a good concordance between the two
methods, qPCR (Figure 2A) and determination of the dis-
tribution of MBD2 reads by ChIPseq (Figure 2B–H). We
also validated 14 cell-specific MBD2 binding sites (Sup-
plementary Figure S2). For many of these, DNA methyla-
tion changes did not seem to be associated with the gain
of MBD2 binding sites in HMLER cells (Supplementary
Figure S2 regions 14q11.2, 12q11.22, 8q22.2 and 16p13.3).
Ten of these regions were amplified by PCR from bisulfite-
modified DNAs. Parallel sequencing of the PCR fragments
validated their methylation status deduced fromMeDP-seq
experiments (Supplementary Table S2). On all the regions
analyzed by qPCR, we confirmed that depletion of MBD2
by siRNA strongly reducedChIP efficiency (Supplementary
Figure S3), confirming the specificity of the antibody.
Endogenous MBD2 binding sites are methylated
MBD2 binding sites (2.5 kb up and down of the cen-
ter of each peak) were visualized by heat maps showing
read density from the MBD2 ChIPseq (MBD2-reads), the
MeDPseq (MeDP-reads) and the negative control, Input-
seq. As expected, strong signal intensities were observed
whenMBD2-reads were plotted against MBD2 peaks (Fig-
ure 1C, HMLER cells and 1F, HMEC-hTERT cells). The
centers of MBD2 peaks were also enriched in MeDP-reads
(Figure 1C and F), indicating that high density in DNA
methylation signals was associated with MBD2 binding
sites. However, K means clustering showed that a subset
of MBD2 peaks is associated with weakly or unmethy-
lated DNA regions (Figure 1C and F). Conversely, DNA
methylation peaks identified by MeDPseq were enriched in
MeDP-reads (Figure 1D and G).
The clustering of MeDP positive regions according to
their MBD2 ChIPseq read densities suggested that up to
a quarter of methylated DNA regions were bound by en-
dogenous MBD2 (Figure 1D and G). Altogether, these
data indicated that, in HMEC-hTERT and HMLER cells,
the endogenous MBD2 proteins associated predominantly
methylated DNA regions, as previously reported from ec-
topic expression of tagged-MBD2 proteins in other cel-
lular models (23,24,53). The relationship between DNA
methylation and MBD2 binding was also observed at Alu
sequences. Alu sequenced are classified into three main
groups depending on the age of the sequence (Repeat-
Masker table download from UCSC). The younger se-
quences, AluY, were found to be more methylated than the
AluJ (older Alu sequences). The AluS, intermediate in age,
exhibited an intermediate level of DNA methylation (Sup-
plementary Figure S4C). The distribution of MBD2 read
densities on these Alu sequences was parallel to the DNA
methylation profiles (Supplementary Figure S4B).
When CpG islands (CGIs, UCSC database) were classi-
fied according to their length and plotted against MeDP-
reads, the shorter CGIs tended to exhibit an increased read
density (Figure 1E and H). These short CGIs were also en-
riched in MBD2 reads (Figure 1E and H), showing that
MBD2 proteins targeted CpG-rich sequences when methy-
lated. The clustering of CGIs according to their MBD2
ChIPseq orMeDPseq read densities led to the identification
of a CGI subgroup where MBD2 binding or DNA methy-
lation were detectable mainly on the shore of the islands,
while another subgroup shown a preferential enrichment at
the core sequences (Supplementary Figure S5A and D).
Identification of enriched K-mer in MBD2 peaks using
RSAT tool failed to identify any sequence specificity except
the presence of CpG sites (Supplementary Table S3). Al-
together, these data indicated that DNA methylation is the
main parameter driving MBD2 deposition.
MBD2 is a major DNA methylation-dependent transcrip-
tional repressor
Transcriptomes of HMEC-hTERT and HMLER cells
were determined from RNAseq experiments. Genes with a
methylated DNA region within ±1 kb of their TSS showed
a low transcriptional level (Supplementary Figure S5). Sim-
ilarly, the transcriptional level of genes with MBD2 peaks
within ±1 kb of their TSS was low (Supplementary Figure
S6). Thus MBD2 binding of promoter was linked to gene
silencing.
The effects of MBD2 depletion and DNA methylation
inhibition on gene transcription were then assessed. High-
throughput sequencing of poly-adenylatedRNA (RNAseq)
were performed with RNA extracted from HMLER cells
treated with either siMBD2 (siRNA targetingMBD2 tran-
scripts (37,54)) or 5-aza-deoxycytidine (DAC).Non-specific
siRNA was used as a control. The analysis of the data
was performed from duplicate RNAseq experiments (Sup-
plementary Table S4). RNAseq analysis indicated a reduc-
tion of 89.5 ± 0.33% of MBD2 mRNA in siMBD2-treated
HMLER cells, while the levels of MeCP2 and MBD1 tran-
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Figure 1. EndogenousMBD2 proteins bindmethylatedDNA regions. (A) Experimental scheme; the transformedmesenchymalHMLER cell line is derived
from the immortalized epithelialHMEC-hTERT cells by oncogenic transformation usingH-RASV12 and SV40T/t oncogenes. Sequencingswere performed
on a pool of five independent experiments. (B) Reads visualization at a MBD2 peak present in each cell line; MBD2 reads in black, input reads in gray,
MBD2 peaks in black bars. Reads matching the + and− strands are on top and bottom, respectively. (C and F) Read density ofMeDPseq,MBD2ChIPseq
and Input at eachMBD2 peak. (D andG) Read density ofMeDPseq,MBD2ChIPseq and input at eachMeDP peak. (E andH) Read density ofMeDPseq,
MBD2 ChIPseq and input at each CpG island (CGI), sorted by their size. (C to E) HMLER cell line. (F to H) HMEC-hTERT cell line.
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Figure 2. Concordance between ChIP-qPCR and ChIP-MBD2 at various genomic locations. (A) ChIP-qPCR experiments mapping MBD2 binding sites,
in HMEC-hTERT cells (green) and HMLER cells (red). Each experiment was performed in duplicate. (B–H) Genome coverage for MeDPseq (black),
MBD2 ChIPseq (orange) and Input-seq (gray) in HMEC-hTERT (upper tracks) and HMLER (bottom tracks) at the seven genomic location tested in A.
Scales are in Fragments Per Million (FPM); Genes in blue, CpG islands in red; qPCR amplicon localization in green.
scripts were not affected (Supplementary Table S4). This
downregulation was also observed at protein level as shown
by western blot analysis (Figure 3A). Digestion of ge-
nomic DNA with HpaII, a restriction enzyme inhibited by
CpG methylation, indicated that DAC induced a global
DNA hypomethylation of HMLER cells (Supplementary
Figure S7). Parallel sequencing of PCR fragments indi-
cated that all the nine methylated genes analyzed were hy-
pomethylated after DAC treatments (Supplementary Table
S2). The classification of the sequencedmolecules according
to their methylation patterns indicated that this hypomethy-
lation was not randomly distributed but corresponded to
a mixture of fully demethylated molecules and unaffected
molecules (data not shown).
Among the 14,814 genes whose expression level could be
reliably assessed in our experiment (see materials and meth-
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Figure 3. MBD2 is a methylation-dependent transcriptional repressor in HMLER cells. (A) Immunoblot analysis of MBD2 proteins in siRNA treated
HMLER cells. (B) Box plots depicting the fold changes (FC) of the transcription levels of genes upregulated upon MBD2 depletion (siMBD2) and the
FC of the same genes in 5-aza-deoxycytidine treated cells (DAC). The upregulated genes were defined as genes exhibiting a FC ≥ 2 with a P value ≤ 0.01.
(C) Box plots depicting the FC of the transcription levels of genes upregulated upon DAC treatments and the FC of the same genes in MBD2-depleted
HMLER cells. (D) Heat maps of genes upregulated or downregulated upon siRNA targeting MBD2. Most genes upregulated by MBD2 depletion were
also upregulated by DAC treatments. (E) Heat maps of genes upregulated or downregulated upon DAC treatments. About 44% of the genes upregulated
uponDAC treatments were also upregulated byMBD2 depletion. (F to I) Integrative analysis of ChIPseq and RNAseq.Mean coverages at gene promoters
were plotted according to their responses to MBD2 siRNA or DAC treatments. Genes were classified into seven groups according to their responses to
either MBD2 depletion or DNA methylation inhibition. N genes: number of genes in each group. For each gene cluster, mean MBD2-read densities and
mean MeDP-read densities at the TSS (± 3 kb) were determined. (F) MBD2-read density at TSS regions of genes classified by their response to siMBD2.
(G) MeDP-read density at TSS regions of genes classified by their response to siMBD2. (H) MBD2-read density at TSS regions of genes classified by their
response to DAC treatments. (I) MeDP-read density at TSS regions of genes classified by their response to DAC treatments.
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ods section), 14.6% (2,164) were upregulated (fold change
greater than 2, and P-value ≤ 0.01) upon siMBD2 treat-
ments. In line with the previous experiments showing that
MBD2 associated methylated DNA regions (Figure 1), a
large proportion (∼70%) of these upregulated genes were
also found upregulated in HMLER cells treated with DAC
(Figure 3B and D). Conversely, a subset of genes (∼40%)
upregulated in DAC-treated HMLER cells was also upreg-
ulated upon MBD2 depletion (Figure 3C and E).
Cross analyses of RNAseq, MBD2 ChIPseq and
MeDPseq experiments were performed by plotting MBD2-
read densities and MeDP-read densities at the TSS (±3
kb) of genes classified in seven clusters according to their
responses to either MBD2 depletion or DNA methylation
inhibition. These data are summarized in Figure 3F–I
and indicated that the upregulated genes upon MBD2
depletion were enriched in MBD2-reads near their TSS in
untreated cells (Figure 3F, red curves). Therefore, MBD2
gene repressions were likely due to MBD2 binding at pro-
moter regions. As expected from the correlation between
MBD2 binding and DNA methylation, the TSS regions of
these upregulated genes were also enriched in MeDP-reads.
(Figure 3G, red curve). Conversely, the genes upregulated
upon hypomethylation of HMLER cells were enriched
in MBD2-reads and MeDP-reads (Figure 3H and I, red
curves).
Enhancers are distal regulatory elements that can im-
pact gene transcription levels. Andersson et al. (55) identi-
fied 66,942 enhancer-TSS association in the human genome.
The clustering of these enhancers according to their MBD2
ChIPseq (Supplementary Figure S8A) or MeDPseq read
densities (Supplementary Figure S8B) indicated that 6.412
and 10,896 enhancers were bound by MBD2 or methy-
lated, respectively, in HMLER cells. Genes associated with
MBD2-positive enhancers or methylated enhancers were
significantly underexpressed (Supplementary Figure S8C).
A subset of these genes was upregulated upon treatments
with siMBD2 (Supplementary Figure S8D) or with DAC
(Supplementary Figure S8E).
Genes close to a CGi, exhibiting amethylated or aMBD2
positive core region, were expressed at a low level when com-
pared with genes associated with unmethylated/MBD2-
free CGi (Supplementary Figure S5B and E). Furthermore,
DAC and siMBD2 treatments led to an upregualtion of
the genes associated with methylated/MBD2-positive CGi-
core regions (Supplementary Figure S5C and F). Although
significantly less affected, the transcription level of genes as-
sociated with methylated or MBD2-positive CGi-shore re-
gions were also downregulated (Supplementary Figure S5B
and E), while inhibition of DNA methylation or MBD2
depletion upregulated these genes (Supplementary Figure
S5C and F). Thus, the repressive forces of DNA methyla-
tion and MBD2 binding seem to be positively correlated
with CpG density.
A similar effect ofMBD2 depletion or inhibition ofDNA
methylation was also observed at repeated elements. De-
pletion of MBD2 or DAC treatments induced a small in-
crease of the steady state level of transcripts corresponding
to AluY elements while the transcription level of the un-
methylated and MBD2-free AluJ elements were unaffected
by these treatments (Supplementary Figure S4A).
These data highlighted the role of MBD2 in the DNA
methylation-dependent gene repression and indicated that,
for a large subset of genes, a loss of MBD2 or a demethyla-
tion have similar effects leading to their upregulation. Thus,
we investigated the contribution of these two epigenetics
events, MBD2 deposition and DNA methylation, on the
downregulation associated with the transformation of im-
mortalized HMEC-hTERT cells.
Dynamics ofMBD2 deposition during oncogenic transforma-
tion
Differential MBD2 binding profiles between HMEC-
hTERT and HMLER cells were determined by quantita-
tive comparison of MBD-peaks (48) identified by ChIPseq
analyses. A high number (17,899) of MBD2 peaks was not
affected by the transformation process (Figure 4A). How-
ever, 5,326 regions (22.9%) associated byMBD2 in HMEC-
hTERT cells lost MBD2 in HMLER, while 7,419 (29.3%)
regions gainedMBD2 binding in HMLER cells when com-
pared with MBD2 profiles in HMEC-hTERT (Figure 4A).
DNA methylation changes were more limited in propor-
tion as HMEC-hTERT and HMLER cells shared 393,631
DNAmethylation peaks while 49,995 regions (11.2%) were
HMEC-hTERT specific and 65,115 regions (14.1%) were
HMLER specific (Figure 4B).
To investigate if MBD2 redistributions were due to lo-
cal DNA methylation changes, we analyzed changes in
MeDPseq read density at MBD2 peaks shared by both cell
lines, or unique to either HMEC-hTERT or HMLER (Fig-
ure 4C). The mean values (number of HMLER MeDP-
reads minus HMEC-hTERT MeDP-reads) were near zero
for all MBD2-peak categories. However, a few outliers did
show a strong decrease of DNA methylation in regions
losing MBD2, and a strong increase of DNA methylation
in regions gaining MBD2. ChIP-qPCR experiments have
exemplified this latter point at several chromosomal loca-
tions such as 10q11.22, 10p15.1 and 1p36.33 (Supplemen-
tary Figure S2A).
Thus, at somemethylated sitesMBD2 deposition was not
observed in HMEC-hTERTcells, while these sites were as-
sociated by MBD2 in HMLER cells. These data indicated
that MBD2 deposition is a dynamic process not exclusively
driven by DNA methylation changes.
MBD2 is involved in the repression of genes downregulated in
oncogenic HMLER cells
Interestingly, genes downregulated during the transforma-
tion of HMEC-hTERT gained MBD2-reads and MeDP-
reads at TSS regions (Figure 4D and E, red curves). Fur-
thermore, more than 50% (1,168 of 2,164) of genes up-
regulated upon MBD2 depletion in HMLER cells were
genes downregulated during the transformation process
(Figure 4F andG). Read densities at theMBD2 peaks near-
est to the annotated TSS of these 1,168 genes were visual-
ized by heat maps showing read density from the MBD2-
reads and the MeDP-reads. At least half of these regions
were enriched in MBD2 in HMLER cells when compared
with HMEC-hTERT cells (Figure 4H).
Data obtained for TFPI2, LINC00842, OSR2, CLDN6
and TNFRSF12A genes illustrate this analysis (Figure 5E–
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Figure 4. Dynamics of MBD2 distribution during oncogenic transformation. (A) Venn diagram depicting the overlap between MBD2 binding sites of
HMEC-HTERT andHMLER cells; in green: regions that significantly loseMBD2 during transformation (P value≤ 0.01), in red: regions that significantly
gainMBD2 during transformation (P value≤ 0.01), in brown: common regions. (B) Venn diagram depicting the overlap between methylated DNA regions
of HMEC-HTERT and HMLER cells; in green: regions that significantly lose DNA methylation during transformation (P value ≤ 0.01), in red: regions
that significantly gain DNA methylation during transformation (P value ≤ 0.01), in brown: common methylated DNA regions. (C) DNA methylation
changes at MBD2 binding sites. Differences in MeDP coverage (FPM, Fragments Per Million) at MBD2 peaks were computed for regions bound by
MBD2 in both cell lines, losing MBD2 or gaining MBD2 in HMLER when compared with HMEC-hTERT. (D and E) Genes were classified according
to their differential expression level (FC) between HMEC-HTERT and HMLER cells. (D) Genes downregulated during oncogenic transformation gain
MBD2-reads near their TSS (red curve), in contrast to unaffected (black curve) or downregulated genes (green curve). (E) Genes downregulated during
oncogenic transformation exhibited gain of MeDP-reads near their TSS (red curve), in contrast to unaffected (black curve) or downregulated genes (green
curve) (F) Venn diagram depicting the overlap between genes upregulated upon MBD2 depletion, DAC treatments and genes downregulated in HMLER
cells when compared with HMEC-hTERT cells. A large proportion of genes downregulated during oncogenic transformation was also upregulated upon
MBD2 depletion and DNA methylation inhibition in the transformed HMLER cell line. (G) Transcription level modification between HMEC-hTERT
and HMLER, of the 2,164 genes upregulated after a siMBD2 treatment in HMLER. Around 1,168 of these genes are expressed at least two times less
in HMLER than in HMEC-hTERT. (H) Read densities from MeDPseq, MBD2 ChIPseq and Input-seq in HMEC-hTERT and HMLER, at the closest
MBD2 peaks in HMLER cells form the TSS of the 1,168 genes identified in (G). Around half of these regions shown an increase MBD2 ChIPseq read
density in HMLER as compared to HMEC-hTERT.
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Figure 5. Examples of genes repressed by MBD2 during oncogenic transformation. (A–D) MBD2 ChIP-qPCR at four genomic regions corresponding
to five gene promoters in the HMEC-hTERT cell line and the transformed HMLER, HME-ZEB1-RAS and HME-shP53-RAS cell lines. These regions
exhibited an increase of MBD2 binding during oncogenic transformation. Each experiment was performed two times independently. (E–I) Relative expres-
sion of five genes in HMEC-hTERT, HMLER treated with a control siRNA (siCtrl), a siRNA targetingMBD2 (siMBD2) or 5-aza-deoxycytidine (DAC),
HME-ZEB1-RAS treated with a control siRNA or a siRNA targetingMBD2 and in HME-shP53-RAS treated with a control siRNA or a siRNA targeting
MBD2. Expression levels were estimated from RNA sequencing duplicates.
I and Supplementary Figure S9A). MBD2 deposition near
the TSS of these genes was increased during oncogenic
transformation (Supplementary Figure S2 and Figure 5A–
D). These genes were downregulated during oncogenic
transformation. Depletion of MBD2 by siRNA led to an
upregulation of these genes in the transformed cell lineHM-
LER (Figure 5E-I). These data indicated that MBD2 par-
ticipated in the establishment of transcriptomic changes in-
duced by oncogenic transformation.
Dynamics of MBD2 deposition upon oncogenic transforma-
tion of immortalized human mammary cells by ZEB1 expres-
sion or P53 depletion
Transcriptomic analyses of HMLER cells treated with
siMBD2 or siControl indicated thatMBD2 depletion led to
an upregulation of genes that are silenced upon the trans-
formation of HMEC-hTERT cells by expressing SV40 T/t
antigens and H-RASV12 genes. It has been shown that the
expression of SV40-derived sequences affects several other
pathways in addition to pRB and P53 (56), raising the pos-
sibility of a SV40-dependent redistribution of MBD2 pro-
teins. Among the mechanisms able to cooperate with the
expression of mutated H-RAS during neoplastic processes,
the expression of the transcription factor ZEB1 or the dis-
ruption of P53-pathways seem to play crucial roles (57,58).
Thus, the involvement of MBD2 in the control of gene ex-
pressionwas investigated in two cellularmodels (Figure 6A)
in which SV40 T/t-antigens expression were replaced by
ZEB1 gene expression (HME-ZEB1-RAS cell line) or a
shRNA targeting P53 transcripts (HME-shP53-RAS cell
line) (35,36). When induced, both cell lines exhibited, as the
HMLER cells, a mesenchymal phenotype and malignant
properties (33,35,36).
We induced MBD2 depletion in HME-ZEB1-RAS and
HME-shP53-RAS cells by siMBD2 treatments, and differ-
ential gene expression profiles between siMBD2 and siCon-
trol treated cells were determined from RNAseq experi-
ments (Figure 6A). Transient transfection of siMBD2 re-
sulted in a reduction of 89.0 ± 0.33% and 91.3 ± 0.25% of
MBD2 transcripts in HME-ZEB1-RAS and HME-shP53-
RAS cells, respectively (Supplementary Table S3), and a
large decrease in MBD2 proteins was also observed from
western blot analyses (Figure 5B).
We identified 584 genes upregulated by MBD2 deple-
tion in at least two cell lines (Figure 5C, fold change
≥ 2, P value ≤ 0.01). A large subset (247, 42.3%) of
these genes were downregulated during oncogenic transfor-
mation (Figure 6D). According to our ChIPseq data, at
least half of the MBD2 peaks near the TSS of these 247
genes shown an increase MBD2 binding in HMLER as
compare to HMEC-hTERT (Supplementary Figure S10).
MBD2 ChIP-qPCR assays performed at genomic loca-
tions previously analyzed (Figure 2 and Supplementary
Figure S2) indicated that MBD2 binding profiles identified
in HMLER cells were frequently similar in HME-ZEB1-
RAS and HME-shP53-RAS cells (Figure 7). Notably, var-
ious losses (17q25.3, 1q21.3) or gains (9q21.12, 10p15.1,
1p36.33, 8q22.2, 16p13.3) of MBD2 binding during onco-
genic transformation were reproduced in these two models
(Figures 5A–D, 7B and Supplementary Figure S9B). As ex-
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Figure 6. MBD2 repressed a common set of genes during oncogenic transformation. (A) Experimental scheme of generation of two cell lines fromHMEC-
hTERT cells by oncogenic transformation. HME-ZEB1-RAS cells were obtained by the expression of the embryonic transcription factor ZEB1 and
H-RASV12, and HME-shP53-RAS cells were obtained by the expression of a shRNA targeting P53 and H-RASV12 genes. (B) Immunoblot analysis of
MBD2 protein level in HME-ZEB1-RAS and HME-shP53-RAS upon siRNA treatment targeting MBD2. (C and D) Heat maps summarizing genes
downregulated (green) or upregulated (red). (C) A set of 548 genes was upregulated in MBD2 knockdown cell lines. (D) Most of these genes upregulated
by siRNA against MBD2 in transformed cell lines were genes that are downregulated during oncogenic transformation.
pected from genome-wide data, parallel sequencing of PCR
fragments obtained from bisulfite-modified DNA indicated
that MBD2 deposition was correlated with DNA methyla-
tion inHME-ZEB1-RAS andHME-shP53-RAS cells at the
10 genes analyzed (Supplementary Table S2).
Altogether, these data suggest that MBD2 is involved in
the regulation of gene expression during the transformation
of HME-ZEB1-RAS and HME-shP53-RAS cells. This role
is thus likely to be independent of the strategies involved in
the abrogation of oncosuppressive barriers.
Genes repressed byMBD2 in transformed cell lines may con-
tribute to the epithelial phenotype
Genes upregulated byMBD2 depletion inHMLER,HME-
ZEB1-RAS and HME-shP53-RAS were investigated for
their Gene Ontology terms and their KEGG pathways
contributions by Gene Set Enrichment Analysis (GSEA).
Enriched Gene Ontology terms were of various natures
but include EXTRACELLULAR REGION, BASE-
MENT MEMBRANE, INTEGRIN COMPLEX (Sup-
plementary Table S5). Enriched KEGG pathways included
KEGG CELL ADHESION MOLECULES CAMS,
KEGG FOCAL ADHESION (Supplementary Table S4).
Although genes repressed byMBD2 in the transformed cell
lines showed a wide diversity of functions, some of them
appeared to be associated with the epithelial phenotype.
Their downregulation by MBD2 may contribute to the
epithelio-mesenchymal transition induced by the oncogenic
transformation of these cells.
DISCUSSION
It has long been known that DNAmethylation patterns are
altered in cancer cells (59,60), these modifications include
global loss of 5-methylcytosines and local hypermethyla-
tions (61,62). Aberrant methylations at CpG islands have
been extensively studied in past years since such hyperme-
thylations have been found at the 5′ regulatory sequences
of many tumor suppressor genes and associated with their
 by guest on N
ovem
ber 29, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2015, Vol. 43, No. 12 5849
Figure 7. MBD2 ChIP-qPCR experiments from HMEC-HTERT, HMLER, HME-ZB1-RAS and HME-shP53 cell lines. Error bars represent average
deviation from two independent experiments. (A) MBD2 binding at several positive and negative regions. (B) MBD2 redistribution in the genome during
oncogenic transformation was frequently concordant in the different transformed cell lines.
silencing (3,63). Although the expression level of genes in
their tissue of origin may influence their methylation status
in the corresponding cancer cells (64), genome-wide studies
have shown that hundreds of genes exhibiting hypermethy-
lated CpG island at their 5′ end were never methylated from
embryonic development onward (3).
From the first studies using in vitro methylated gene ex-
pression vectors, accumulating evidence indicates that the
methylation of CpG rich sequences at the 5′ end of a gene
provides a strong signal for maintaining/inducing gene si-
lencing (65,66). In cell lines, inhibition of DNA methyla-
tion by cytosine analog (17) orDNMT1knockdown (67,68)
leads to the re-expression of many methylated genes. This
relationship has been also observed in living animals. For
example, conditional inactivation of DNMT1 causes aber-
rant gene expression of many genes in mouse fibroblasts
(69).
Histone deacetylation, histone methylation and chro-
matin compaction are major events involved in gene repres-
sion and DNA methylation is associated with these chro-
matin modifications (70,71). The importance of proteins as-
sociating DNA sequences was suggested many years ago
by in vitro transcription assays showing that the methyla-
tion of templates does not prevent transcription (72), while
methylated vectors are not transcribed in living cell (65,73).
From these pioneering works, it had been established that
specific proteins from different families recognize methy-
lated DNA. Among these proteins, the proteins contain-
ing a methyl-CpG binding domain were the first discov-
ered (13,74) and many studies have indicated that theMBD
proteins are good candidates for interpreting the methyla-
tion signals (9,10). In contrast with transcription factors,
the sequence specificities of these proteins does not seem to
be very stringent. In vitro assays indicate that MBD1 has
a higher affinity for meCGCA or TGmeCGCAsites (75),
while MeCP2 preferentially associates methylated CpG fol-
lowed by a run of four or more A/T bases (76). However,
the presence of symmetrically methylated CpGs seems to
be the major determinant of their binding since multiple
methylated CpGs can override their sequence preference at
methylated sites (75,76). Biochemical studies ofMBD2have
also indicated a preference for a short sequence CmeCGA
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(77). In line with this finding, CCG sequences are preferen-
tially found in manyMBD2 genomic targets (77). However,
this observation might be biased by over-representation of
methylated CpG-rich sequences among the genomic targets
of MBD2 (37,78–82).
The intracellular concentrations of each MBD protein
may also influence their targeting, for example, in neurons
MeCP2 is highly expressed and tracks methyl CpG densi-
ties (83). In HeLa cells, clearance of MBD2 by siRNA at
the BRCA1-NBR2 locus does not promote the binding of
the endogenousMeCP2 orMBD1 proteins. However, over-
expression of a vector coding for MeCP2 induces its bind-
ing at this site (37). In mice, knockdown of the individual
MBDproteins,MeCP2,MBD1 orMBD2 (84–86) results in
the upregulation of many genes but not in global misexpres-
sion of endogenous methylated genes. Thus, other members
of the family might compensate for the absence of a spe-
cific MBD since many cell and tissue types express multiple
MBDproteins. Nevertheless, the deletion of a specificMBD
protein leads to specific phenotypes (10), indicating a func-
tional specificity for these proteins and gene candidate anal-
ysis has provided examples of gene specific upregulation.
Altogether, these data argue against a full redundancy be-
tweenMeCP2,MBD1 andMBD2, and suggest that the dis-
tribution of MBD proteins across the methylated regions
might represent an additional level in the interpretation of
the DNA methylation marks. Indeed, our analysis of the
MBD2 binding profiles during the oncogenic transforma-
tion of immortalized human mammary cells indicates that
the modifications of MBD2 distribution are, for a subset of
genes, independent of DNA methylations changes.
Although chromatin immuno-precipitation of endoge-
nous MBD proteins has proven challenging (23,24,53), we
have performed ChIPseq against endogenous MBD2 pro-
teins in two isogenic cell lines in order to take into ac-
count the cell-specific regulation of MBD2. Despite the
significant differences in technologies, ChIPseq data cor-
related well with those obtained from MBD2 ChIP-chip
experiments. ChIP-qPCR on arbitrary chosen negative or
positive regions also showed a good concordance between
data obtained from ChIP-qPCR and ChIPseq experiments.
Furthermore, MBD2 depletion upon siRNA treatments
strongly reduced MBD2 ChIP efficiency on these regions.
Thus, the data obtained from ChIPseq experiments per-
formed from antibodies directed against the endogenous
proteins seem to be representative of the MBD2 binding
profiles of the studied cell lines.
The identification of MBD2 binding sites has provided
an opportunity for the search of in vivo sequence prefer-
ences driving MBD2 deposition. In line with previous bio-
chemical analyses, we did not detect any over-represented
sequences in theMBD2 peaks, CG sequence excepted. Nev-
ertheless, the proposed preference for a CCG sequence (77)
may escape this analysis since this short sequence is over-
represented in CpG islands.
The lack of consensus sequence and the strong enrich-
ment in methylated CpGs at MBD2 peaks support a di-
rect relationship between DNA methylation and MBD2
binding, at least in HMEC-hTERT and HMLER cells.
The method used for the mapping of methylated DNA
regions was based on the selection of methylated DNA
fragments using recombinant proteins associating methy-
lated CpGs. Thus, selected fragments can contain addi-
tional CpGs that were not methylated, preventing a di-
rect evaluation of the methylated-CpG density. Neverthe-
less, combining themapping ofMBD2-tagged proteins with
single base pair resolution methylomes allow the establish-
ment of a linear relationship between MBD2 enrichment
and methylation density, in neuronal cells (24). It should
be noted that, for a minority of MBD2 binding sites, ad-
ditional events participate in MBD2 deposition. Indeed,
we observed that some MBD2 peaks were not associated
with methylated DNA regions. In line with this observa-
tion, it has been proposed that theNuRD complexmediates
the binding of MBD2 to unmethylated DNA regions (24).
Altogether, these data indicate that the main determinant
for MBD2 binding is the methylation status of the DNA
in both HMEC-hTERT and HMLER cells. Furthermore,
about 25% of the methylated DNA regions identified from
MeDPseq matched MBD2 binding sites. Although we can-
not exclude that othermethyl DNAbinding proteins associ-
ated the same methylated DNA regions (82), MBD2 seems
to be an important player in the epigenetic machinery in
HMEC-hTERT and HMLER cells.
MBD2 knockdown experiments were also in favor of
an involvement of MBD2 in the downregulation of many
methylated genes. Depletion of MBD2 by siRNA induced
an upregulation of about 2,000 genes and 70% of these
genes were also upregulated by a DAC treatments in HM-
LER cells. The analysis of TSS regions of genes upregulated
uponMBD2depletion in untreatedHMLERcells indicated
that these genes were enriched inMBD2 andDNAmethyla-
tion marks when compared with genes unaffected or down-
regulated byMBD2 siRNA. Conversely, the TSS regions of
genes upregulated by DAC were enriched in MBD2 when
compared with unaffected or downregulated genes upon
DNA hypomethylation. The impact of MBD2 depletion on
gene expression was globally less stringent than DAC treat-
ments. DNA hypomethylation induced the upregulation of
a higher number of genes thanMBD2 depletion and higher
fold changes in gene expression. It is tempting to explain
these differences by the involvement of otherMBDproteins
and of MBP proteins from other families in the repression
of methylated genes. However, the distinct nature of both
treatments prevents a quantitative comparison, since data
may be biased by differences in treatment efficiencies and ki-
netics. Further analysis of our data at non-promoter regions
indicated that DNAmethylation at enhancer sequences was
correlated with low transcriptional activity of the genes po-
tentially regulated by these elements, as previously reported
in embryonic stem cell (87). Furthermore, a correlation be-
tween MBD2 deposition at enhancer sequences and low
transcriptional activity was also observed, suggesting that
MBD2 may modulate the activity of regulatory regions not
directly associated with the 5′ end gene regions. These data
also confirm that MBD2 plays an important role in the in-
terpretation of DNA methylation signal in HMLER cells.
In the isogenic cellular model studied, the immortal-
ized cells (HMECT-hTERT) and the oncogenic cells HM-
LER, most of the MBD2 binding sites were shared by
both cell lines. However, oncogenic transformation was
associated with a partial redistribution of MBD2 pro-
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teins, 5,326 MBD2-positive regions in HMEC-hTERT lost
MBD2 binding in HMLER, while 7,419 regions in in
HMEC-hTERT gained MBD2 in HMLER cells. Such re-
distribution may be in part explained by local DNAmethy-
lation changes. Nevertheless, the majority of the regions
gaining or losing MBD2 in HMLER exhibited comparable
MeDPseq-read densities in both cell lines. This redistribu-
tion of MBD2 was also observed at promoter regions and
associated with the modulation of the transcriptional ac-
tivity of the corresponding genes. Among the 3,160 genes
downregulated in transformed cells, 380 genes were methy-
lated at their promoter regions in both cell lines, specifically
associated by MBD2 in HMLER cells, and upregulated
upon MBD2 depletion in HMLER. Thus, the redistribu-
tion of MBD2 proteins occurring in HMLER cells seemed,
at least for a subset of genes, independent of DNA methy-
lation changes. As observed for MeCP2 (76), not all the po-
tential MBD2 binding sites were precipitated byMBD2 an-
tibodies suggesting that additional factors are involved in
MBD2 deposition. Several hypotheses, not mutually exclu-
sive, could explain these specific profiles: competition with
transcription factors (26), steric hindrance due to chromatin
proteins, stabilization of the interaction between MBD2
and methylated DNA by other proteins. Although the pre-
cise mechanisms driving the specificity of the MBD fam-
ily protein profiles remain to be experimentally established,
redistribution of MBD2 proteins across methylated DNA
regions seems to be associated with the transformation pro-
cess(es) occurring in the immortalized human mammary
cell lines cells expressing the SV40 T/t antigens and H-
RASV12, or either ZEB1 or a shP53.
HMLER cells were obtained by sequential introduction
of hTERT, SV40 large T/small t antigens, oncogenic H-
RASV12 genes (33,35) in primary cultures of human mam-
mary epithelial cells. The expression of SV40 sequences
affects multiple pathways in human mammary cells (56),
raising questions about a SV40-dependent redistribution
of MBD2 proteins. We also suppressed the oncosuppres-
sive barriers in HMEC-hTERT cells either by ectopic ex-
pression of the transcription factor ZEB1 or a P53 de-
pletion. The resulting HMLER cell lines, after introduc-
tion ofH-RASV12 gene, exhibited oncogenic properties and
a mesenchymal phenotype (36). In HME-ZEB1-RAS and
HME-shP53-RAS, most of the 14 regions exhibiting a gain
or loss of MBD2 in HMLER cells showed similar MBD2
binding changes. Furthermore, hundreds of genes upregu-
lated by MBD2 depletion in HME-ZEB1-RAS and HME-
shP53-RAS cells were also upregulated in HMLER upon
treatment with the siRNA targeting MBD2. Thus, the dy-
namics of MBD2 deposition do seem to be independent of
the strategy used for overcoming the oncosuppresive bar-
riers. However, we cannot exclude that a large part of the
MBD2 redistributions observed are linked to the intro-
duction of H-RASV12. MBD2 redistribution and its conse-
quences on gene expression have been investigated in exper-
imental models. Nevertheless, it should be noted that ZEB1
reactivation is a common feature of aggressive and undiffer-
entiated human breast cancers, especially in the claudin-low
intrinsic subtype (88), and that alterations of P53-pathways
play a crucial role in human cancers (89).
The involvement of MBD2 in the oncogenic process has
been already suggested. For example, MBD2 repression of
Lect2 genemay participate in polyp formations viaWnt sig-
naling pathways in mice carrying ApcMin alleles (29). In hu-
man mammary cancer cell lines, the repression of DAPK1
mediated by MBD2 seems to actively participate in main-
tenance of their aggressive phenotypes when xenografted
into immuno-deficient mice (90). None of these genes was
targeted by MBD2 during transformation in the cellular
models studied here (Supplementary Table S4). The role
of MBD2 in transformation is likely to be due to the re-
pression of multiple targets, which may differ between ex-
perimental models or pathologies. Nevertheless, the genes
downregulated during the oncogenic transformation of im-
mortalized human mammary cells seem to be preferential
targets for MBD2. Furthermore, these genes were prefer-
entially reactivated by MBD2 depletion and enriched in
MBD2 binding sites in cell lines constructed from the dis-
ruption of oncosuppressive barriers in immortalized cells.
It has been reported that in similar cellular models, the ma-
jor methylation changes at gene promoters occur during
the immortalization step, while subsequent steps of onco-
genic transformation are associated with subtle modifica-
tions of DNAmethylation and gene expression (34). In line
with these data, we only find minor modifications of the
DNA methylation patterns between the immortalized cells,
HMEC-hTERT and the oncogenic HMLER cells. Alto-
gether, these data emphasize, at genome-wide level, the role
played by the epigenetics readers of DNAmethylation dur-
ing oncogenic transformation. The reprograming of cancer
cells may be due to a redistribution of methyl-DNA binding
proteins in addition to DNA methylation alterations.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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